These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 8769200

  • 1. UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. U.K. Neoral Study Group.
    Moore RH.
    Transplant Proc; 1996 Aug; 28(4):2202-3. PubMed ID: 8769200
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU, Grosso S, de Boccardo G, Vásquez MC, Schiavelli RO, Sabbatiello RR, Casadei DH, Rial MC, Jost LJ, Túrin MD, Agost Carreño C A, Maggiora EC, Gadea MM.
    Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL, Zhao M, Zhu YH, Qi J, Wang LM, Wang YW.
    Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract] [Full Text] [Related]

  • 6. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B, Korn A.
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients.
    Rosental R, Bicans J, Berzina R, Zezina L.
    Transplant Proc; 1995 Dec; 27(6):3436-7. PubMed ID: 8540038
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Conventional versus Neoral cyclosporine in renal transplantation.
    Rovelli E, Bucci A, Maldifassi P, Belfiore A, D'Amico G.
    Transplant Proc; 1998 Aug; 30(5):1764-5. PubMed ID: 9723272
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
    Gaston R, Alloway RR, Gaber AO, Rossi SJ, Schroeder TJ, Irish WD, Canafax DM, First MR.
    Transplant Proc; 1999 Aug; 31(1-2):326-7. PubMed ID: 10083128
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR, Weiskittel P, Shah M, Peddi VR, Canafax D, Schroeder TJ.
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.